The Commission is proposing an ambitious revision of the EU pharmaceutical legislation (including a Directive and a Regulation), in order to, inter alia, create a Single Market for medicines, ensure an innovation-friendly framework for research and production and reduce the administrative burden.
The Report on Competition policy, published annually, provides detailed information on the most important policy and legislative initiatives, and on decisions adopted by the European Commission in application of EU competition law during the previous year.
EESC opinion NAT/908 - Plants produced by new genomic techniques.
The way forward to deepen the single market through digitalisation
Exploratory opinion requested by the Spanish presidency of the EU on the competitiveness of EU's industry.
As committed during the negotiations on the long-term EU budget 2021-2027, the European Commission has on 20 June 2023 completed its proposal for a next generation of own resources. The package includes a new temporary statistical own resource based on company profits. The Commission also proposes to adjust the own resources proposals based on the Emissions Trading System (ETS) and Carbon Border Adjustment Mechanism (CBAM) compared to the original proposals from December 2021.
The opinion will provide few but meaningful and concrete recommendations, reflecting the contributions made in the sections' and CCMI own-initiative opinions addressing the Blue Deal from their respective perspectives.